scholarly journals Tumor-Associated Glycans and Their Role in Gynecological Cancers: Accelerating Translational Research by Novel High-Throughput Approaches

Metabolites ◽  
2012 ◽  
Vol 2 (4) ◽  
pp. 913-939 ◽  
Author(s):  
Tatiana Pochechueva ◽  
Francis Jacob ◽  
Andre Fedier ◽  
Viola Heinzelmann-Schwarz
Keyword(s):  
Translational Research ◽  
High Throughput ◽  
Gynecological Cancers

scholarly journals Translational informatics: enabling high-throughput research paradigms

2009 ◽  
Vol 39 (3) ◽  
pp. 131-140 ◽  
Author(s):  
Philip R. O. Payne ◽  
Peter J. Embi ◽  
Chandan K. Sen
Keyword(s):  
Translational Research ◽  
High Throughput ◽  
Large Scale ◽  
Data Sets ◽  
Biomedical Data ◽  
Current State ◽  
Common Thread ◽  
Translational Informatics ◽  
Research Domains ◽  
Clinical And Translational Research

A common thread throughout the clinical and translational research domains is the need to collect, manage, integrate, analyze, and disseminate large-scale, heterogeneous biomedical data sets. However, well-established and broadly adopted theoretical and practical frameworks and models intended to address such needs are conspicuously absent in the published literature or other reputable knowledge sources. Instead, the development and execution of multidisciplinary, clinical, or translational studies are significantly limited by the propagation of “silos” of both data and expertise. Motivated by this fundamental challenge, we report upon the current state and evolution of biomedical informatics as it pertains to the conduct of high-throughput clinical and translational research and will present both a conceptual and practical framework for the design and execution of informatics-enabled studies. The objective of presenting such findings and constructs is to provide the clinical and translational research community with a common frame of reference for discussing and expanding upon such models and methodologies.

scholarly journals Integrated, automated maintenance, expansion and differentiation of 2D and 3D patient-derived cellular models for high throughput drug screening

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Ibrahim Boussaad ◽  
Gérald Cruciani ◽  
Silvia Bolognin ◽  
Paul Antony ◽  
Claire M. Dording ◽  
...  
Keyword(s):  
Translational Research ◽  
Precision Medicine ◽  
High Throughput ◽  
Neural Progenitor Cells ◽  
Human Fibroblasts ◽  
Cell Types ◽  
Cellular Models ◽  
Automated Platform ◽  
Induced Pluripotent ◽  
Different Cell Types

AbstractPatient-derived cellular models become an increasingly powerful tool to model human diseases for precision medicine approaches. The identification of robust cellular disease phenotypes in these models paved the way towards high throughput screenings (HTS) including the implementation of laboratory advanced automation. However, maintenance and expansion of cells for HTS remains largely manual work. Here, we describe an integrated, complex automated platform for HTS in a translational research setting also designed for maintenance and expansion of different cell types. The comprehensive design allows automation of all cultivation steps and is flexible for development of methods for variable cell types. We demonstrate protocols for controlled cell seeding, splitting and expansion of human fibroblasts, induced pluripotent stem cells (iPSC), and neural progenitor cells (NPC) that allow for subsequent differentiation into different cell types and image-based multiparametric screening. Furthermore, we provide automated protocols for neuronal differentiation of NPC in 2D culture and 3D midbrain organoids for HTS. The flexibility of this multitask platform makes it an ideal solution for translational research settings involving experiments on different patient-derived cellular models for precision medicine.

Bioinformatics for Cancer Management in the Post-Genome Era

2006 ◽  
Vol 5 (2) ◽  
pp. 169-175 ◽  
Author(s):  
Masuko Katoh ◽  
Masaru Katoh
Keyword(s):  
Translational Research ◽  
Cancer Patients ◽  
High Throughput ◽  
Human Cancer ◽  
Genetic Alterations ◽  
Oligonucleotide Array ◽  
Omics Data ◽  
Apoptosis Resistance ◽  
Cancer Management ◽  
High Throughput Technology

Human cancer is caused by multiple factors, such as genetic predisposition, chronic persistent inflammation, environmental factors, life style, and aging. Dysregulated proliferation, dysregulated adhesion, resistance to apoptosis, resistance to senescence, and resistance to anti-cancer drugs are features of cancer cells. Accumulation of multiple epigenetic changes and genetic alterations of cancer-associated genes during multi-stage carcinogenesis results in more malignant phenotypes. Post-genome science is characterized by omics data related to genome, transcriptome, proteome, metabolome, interactome, and epigenome as well as by high-throughput technology, such as whole-genome tiling oligonucleotide array, array CGH with 32,433 overlapping BAC clones, transcriptome microarray, mass spectrometry, tissue-based expression array, and cell-based transfection array. Benchtop oncology supplies Desktop oncology with large amounts of omics data produced by high-throughput technology. Desktop oncology establishes knowledge on cancer-related biomarkers, such as predisposition markers, diagnostic markers, prognostic markers, and therapeutic markers, by using bioinformatics and human intelligence of experts for data mining and text mining. Bedside oncology applies the knowledge established by Desktop oncology to determine therapeutics for cancer patients. Antibody drugs (Trastuzumab/Herceptin, Cetuximab/Erbitux, Bevacizumab/Avastin, et cetera), small molecule inhibitors for tyrosine kinases (Gefitinib/Iressa, Erlotinib/Tarceva, Imatinib/Gleevec, et cetera), conventional cytotoxic drugs, and anti-hormonal drugs are used for cancer chemotherapy. Biomarker monitoring contributes to therapeutic optional choice and drug dosage determination for cancer patients. Knowledge on biomarkers is feedforwarded from desktop to bedside in the translational research, and then biomarker monitoring is feedbacked from bedside to desktop in the reverse translational research. Desktop oncology is indispensable for cancer research in the post-genome era. Combination of genetic screening for cancer predisposition in the general population and precise selection of therapeutic options during cancer management could contribute to the realization of personalized prevention and to dramatically improve the prognosis of cancer patients in the future.

Report From the 20th Meeting of the European Society of Gynaecological Oncology (ESGO 2017)

2018 ◽  
Vol 28 (5) ◽  
pp. 1050-1053 ◽  
Author(s):  
Kamil Zalewski ◽  
Elisa Piovano ◽  
Zoia Razumova ◽  
Ilker Selcuk ◽  
Tanja Nikolova
Keyword(s):  
Translational Research ◽  
European Society ◽  
State Of The Art ◽  
Gynecological Cancers ◽  
Poster Abstract ◽  
Scientific Level ◽  
Cervical Cancers ◽  
Gynaecological Oncology ◽  
Emerging Trends ◽  
First Time

AbstractThis is a report from the 20th Meeting of the European Society of Gynaecological Oncology (ESGO) held in Vienna, Austria on November 4 to 7, 2017. The conference offered state-of-the-art educational sessions and oral and poster abstract presentations. The general sessions throughout the meeting focused not only on prevention, screening, diagnosis, treatment, and translational research but also emerging trends, and current innovations in gynecological cancers were discussed. The ESGO-European Society for Radiotherapy and Oncology-European Society of Pathology guidelines on management of cervical cancers were reported for the first time in public. Here, we highlight the key results of the latest trials for gynecological cancers presented for the first time at the ESGO 2017 Meeting and added great value to the congress scientific level.

scholarly journals Gynecological Cancers Translational, Research Implementation, and Harmonization: Gynecologic Cancer InterGroup Consensus and Still Open Questions

Cells ◽  
2019 ◽  
Vol 8 (3) ◽  
pp. 200 ◽  
Author(s):  
Marina Bagnoli ◽  
Ting Shi ◽  
Charlie Gourley ◽  
Paul Speiser ◽  
Alexander Reuss ◽  
...  
Keyword(s):  
Translational Research ◽  
Gynecological Cancer ◽  
Gynecologic Cancer ◽  
Clinical Trial Design ◽  
Sample Collection ◽  
Gynecological Cancers ◽  
Research Committee ◽  
Open Questions ◽  
Biomarker Validation ◽  
Translational Studies

In the era of personalized medicine, the introduction of translational studies in clinical trials has substantially increased their costs, but provides the possibility of improving the productivity of trials with a better selection of recruited patients. With the overall goal of creating a roadmap to improve translational design for future gynecological cancer trials and of defining translational goals, a main discussion was held during a brainstorming day of the Gynecologic Cancer InterGroup (GCIG) Translational Research Committee and overall conclusions are here reported. A particular emphasis was dedicated to the new frontier of the immunoprofiling of gynecological cancers. The discussion pointed out that to maximize patients’ benefit, translational studies should be integral to clinical trial design with standardization and optimization of procedures including a harmonization program of Standard Operating Procedures. Pathology-reviewed sample collection should be mandatory and ensured by dedicated funding. Biomarker validation and development should be made public and transparent to ensure rapid progresses with positive outcomes for patients. Guidelines/templates for patients’ informed consent are needed. Importantly for the public, recognized goals are to increase the involvement of advocates and to improve the reporting of translational data in a forum accessible to patients.

Sign in / Sign up

Export Citation Format

Share Document